Mortgage applications jumped 1.2 percent from a week ago, according to data from the Mortgage Bankers Association.
The group said falling mortgage rates are behind the uptick — and falling mortgage rates are due to a broader slowdown in wages and economic growth.
"Purchase applications continued to be hampered by broader weakness in the housing market and declined slightly over the week, with the index slipping to its lowest level since 2014,” said Joel Kan, vice president and deputy chief economist at MBA.
The average contract interest rate for 30-year fixed-rate mortgages fell 16 basis points from 6.58 percent to 6.42 percent.
There was also a notable bump in refinancing applications. Their share of mortgage activity increased to 30.7 percent from 30.3 percent a week ago, also on the back of falling mortgage interest rates.
This is still down 80 percent from a year ago, when rock-bottom rates led to a spree of refinancing activity.
Conditions have been mostly nice for travelers flying ahead of and on Christmas Day, but some naughty disruptions plagued those flying with Southwest Airlines again this year.
Gift cards make great stocking stuffers — just as long as you don't stuff them in a drawer and forget about them after the holidays.
Big Business This Week is a guided tour through the biggest market stories of the week, from winning stocks to brutal dips to the facts and forecasts generating buzz on Wall Street.
Bristol Myers Squibb agreed to buy schizophrenia drug maker Karuna Therapeutics in a $14 billion deal.
Supermarket chain Ralphs is facing a new lawsuit from the state of California.
Shake Shack is giving out free fried chicken sandwiches, bacon cheese fries and milkshakes nationwide.
The IRS is announcing a voluntary disclosure program.
Lionsgate announced its studio division is going to spin off in a merger with Screaming Eagle Acquisition Corp., which is a special purpose acquisition company.
A new report suggests that it's getting more difficult for an average American to afford a home.
The Food and Drug Administration warned consumers about a copycat version of the diabetes drug Ozempic.
